{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:44:37Z","timestamp":1769107477396,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec>\n                    <jats:title>Study Objective<\/jats:title>\n                    <jats:p>\n                      To determine the effect of dobutamine versus milrinone on out\u2010of\u2010hospital mortality in the treatment of patients with acute decompensated heart failure (\n                      <jats:styled-content style=\"fixed-case\">ADHF<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Propensity score weighted retrospective cohort study with mortality as the primary outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>An academic health care system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>\n                      Five hundred adult patients with a prior history of heart failure who survived a hospitalization for\n                      <jats:styled-content style=\"fixed-case\">ADHF<\/jats:styled-content>\n                      that included treatment with dobutamine or milrinone between January 1, 2006, and April 30, 2014.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>\n                      <jats:styled-content style=\"fixed-case\">ADHF<\/jats:styled-content>\n                      events were defined as a hospitalization with receipt of an intravenous loop diuretic or a brain\u2010type natriuretic peptide (\n                      <jats:styled-content style=\"fixed-case\">BNP<\/jats:styled-content>\n                      ) value greater than 400\u00a0pg\/ml during the hospitalization. Patients were followed until death or 180\u00a0days from hospital discharge. Risk ratios (\n                      <jats:styled-content style=\"fixed-case\">RRs<\/jats:styled-content>\n                      ) for mortality associated with dobutamine compared with milrinone were calculated at 15, 30, and 180\u00a0days postdischarge using Poisson regression with robust error variance. Mean age was 62.7\u00a0years, 65.4% were male, and 48.2% had a mean left ventricular ejection fraction (\n                      <jats:styled-content style=\"fixed-case\">LVEF<\/jats:styled-content>\n                      ) of 40% or lower. Overall, 55 (18%) of dobutamine\u2010treated versus 23 (12%) of milrinone\u2010treated patients died during follow\u2010up (\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      1.27, 95%\n                      <jats:styled-content style=\"fixed-case\">confidence interval [CI]<\/jats:styled-content>\n                      0.76\u20132.13, p=0.360). For death from cardiovascular causes, the\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      for dobutamine was 1.49 (95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      0.79\u20132.82, p=0.214). For death from worsening heart failure, the\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      for dobutamine was 2.55 (95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      1.07\u20136.10, p=0.035). A trend toward significance was observed at day 15 after discharge for all mortality analyses (all p values &lt; 0.10).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Dobutamine was associated with higher short\u2010term out\u2010of\u2010hospital mortality compared with milrinone in patients with\n                      <jats:styled-content style=\"fixed-case\">ADHF<\/jats:styled-content>\n                      . These results replicate and extend prior associations with mortality and should be confirmed in a prospective study.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.1939","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T09:33:34Z","timestamp":1493976814000},"page":"662-672","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effect of Inpatient Dobutamine versus Milrinone on Out\u2010of\u2010Hospital Mortality in Patients with Acute Decompensated Heart Failure"],"prefix":"10.1002","volume":"37","author":[{"given":"Jordan B.","family":"King","sequence":"first","affiliation":[{"name":"Department of Pharmacy Kaiser Permanente Colorado Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmee U.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine School of Medicine, University of Utah Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Sainski\u2010Nguyen","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy College of Pharmacy, University of Utah Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Biskupiak","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy College of Pharmacy, University of Utah Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Munger","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine School of Medicine, University of Utah Salt Lake City Utah"},{"name":"Department of Pharmacotherapy College of Pharmacy, University of Utah Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam P.","family":"Bress","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences School of Medicine, University of Utah Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000350"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.051620"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.748"},{"key":"e_1_2_6_5_1","first-page":"510","article-title":"Acute decompensated heart failure: contemporary medical management","volume":"36","author":"Joseph SM","year":"2009","journal-title":"Tex Heart Inst J"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.07.011"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2010.05.021"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.019"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eus027"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1701"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000112368"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2009.08.004"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.284"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1515\/ijb-2012-0030"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh090"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X0900900206"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3462-1_3"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.03.051"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90388-3"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.899294"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000296273.72952.39"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.11.009"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.728840"},{"key":"e_1_2_6_25_1","first-page":"438","article-title":"Vasopressor and inotropic management of patients with septic shock","volume":"40","author":"Pollard S","year":"2015","journal-title":"Pharm Therapeut"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1939","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:06:25Z","timestamp":1761066385000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1002\/phar.1939"],"URL":"https:\/\/doi.org\/10.1002\/phar.1939","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"2017-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}